Geode Capital Management
AVDL

Geode Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Geode Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,156,356
Closed -$46.5M – 4523
2025
Q4 		$46.5M Sell
2,156,356
-19,421
-0.9% -$377K ﹤0.01% 1531
2025
Q3 		$33.2M Buy
2,175,777
+6,759
+0.3% +$87.9K ﹤0.01% 1728
2025
Q2 		$19.2M Buy
2,169,018
+979,422
+82% +$8.6M ﹤0.01% 1978
2025
Q1 		$9.31M Buy
1,189,596
+24,345
+2% +$204K ﹤0.01% 2334
2024
Q4 		$12.2M Buy
1,165,251
+10,886
+0.9% +$132K ﹤0.01% 2238
2024
Q3 		$15.1M Sell
1,154,365
-6,455
-0.6% -$98.3K ﹤0.01% 2138
2024
Q2 		$16.3M Buy
1,160,820
+1,056,593
+1,014% +$17.2M ﹤0.01% 2043
2024
Q1 		$1.76M Buy
104,227
+11,644
+13% +$173K ﹤0.01% 3162
2023
Q4 		$1.31M Sell
92,583
-1,822
-2% -$21.4K ﹤0.01% 3241
2023
Q3 		$972K Buy
94,405
+14,003
+17% +$188K ﹤0.01% 3333
2023
Q2 		$1.33M Buy
80,402
+399
+0.5% +$5.19K ﹤0.01% 3247
2023
Q1 		$733K Buy
80,003
+924
+1% +$7.6K ﹤0.01% 3493
2022
Q4 		$566K Buy
79,079
+38,551
+95% +$270K ﹤0.01% 3608
2022
Q3 		$203K Hold
40,528
– – ﹤0.01% 4205
2022
Q2 		$98K Hold
40,528
– – ﹤0.01% 4600
2022
Q1 		$276K Hold
40,528
– – ﹤0.01% 4219
2021
Q4 		$327K Hold
40,528
– – ﹤0.01% 4256
2021
Q3 		$397K Hold
40,528
– – ﹤0.01% 4141
2021
Q2 		$272K Sell
40,528
-1,917
-5% -$15.2K ﹤0.01% 4206
2021
Q1 		$383K Buy
42,445
+7,893
+23% +$63.8K ﹤0.01% 3897
2020
Q4 		$230K Hold
34,552
– – ﹤0.01% 3843
2020
Q3 		$174K Buy
34,552
+7,157
+26% +$52.1K ﹤0.01% 3756
2020
Q2 		$221K Buy
27,395
+1,282
+5% +$11.3K ﹤0.01% 3637
2020
Q1 		$207K Sell
26,113
-20,107
-44% -$154K ﹤0.01% 3540
2019
Q4 		$348K Hold
46,220
– – ﹤0.01% 3624
2019
Q3 		$192K Hold
46,220
– – ﹤0.01% 3781
2019
Q2 		$133K Buy
46,220
+9,221
+25% +$15.8K ﹤0.01% 3888
2019
Q1 		$53K Hold
36,999
– – ﹤0.01% 4013
2018
Q4 		$95K Hold
36,999
– – ﹤0.01% 3867
2018
Q3 		$162K Hold
36,999
– – ﹤0.01% 3811
2018
Q2 		$226K Buy
36,999
+24,319
+192% +$171K ﹤0.01% 3684
2018
Q1 		$92K Hold
12,680
– – ﹤0.01% 3862
2017
Q4 		$103K Sell
12,680
-9,372
-42% -$87.9K ﹤0.01% 3812
2017
Q3 		$231K Sell
22,052
-11,274
-34% -$108K ﹤0.01% 3625
2017
Q2 		$367K Buy
33,326
+2,063
+7% +$20.7K ﹤0.01% 3466
2017
Q1 		$302K Buy
+31,263
New +$313K ﹤0.01% 3507
2016
Q4 		– Sell
-22,218
Closed -$275K – 4037
2016
Q3 		$275K Sell
22,218
-3,929
-15% -$51.3K ﹤0.01% 3481
2016
Q2 		$280K Buy
26,147
+11,253
+76% +$120K ﹤0.01% 3452
2016
Q1 		$164 Sell
14,894
-102
-0.7% -$1.01K ﹤0.01% 3689
2015
Q4 		$183K Buy
14,996
+1,660
+12% +$25.9K ﹤0.01% 3716
2015
Q3 		$217K Sell
13,336
-522
-4% -$11.5K ﹤0.01% 3653
2015
Q2 		$293K Buy
13,858
+1,314
+10% +$23.6K ﹤0.01% 3436
2015
Q1 		$225K Buy
12,544
+613
+5% +$9.6K ﹤0.01% 3535
2014
Q4 		$203K Buy
+11,931
New +$170K ﹤0.01% 3579

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Geode Capital Management's AVDL Position: Q1 2026 in Review

Geode Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 2,156,356 shares — an estimated $46.5M sold.

Geode Capital Management first reported a position in AVDL in Q4 2014 and held it in 44 quarters. The position peaked at $46.5M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Geode Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 2,156,356 Avadel Pharmaceuticals shares in Q1 2026, an estimated $46.5M.
  • Geode Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 44 quarters.
  • Geode Capital Management's Avadel Pharmaceuticals position peaked at $46.5M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.